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Abstract 
Development of sensitive and specific biomarkers, preferably those circulating in body fluids is 
critical for early diagnosis of cancer. This study performed profiling of microRNAs (miRNAs) in 
exocrine pancreatic secretions (pancreatic juice) by microarray analysis utilizing pancreatic juice 
from 6 pancreatic ductal adenocarcinoma (PDAC) patients and two pooled samples from 6 
non-pancreatic, non-healthy (NPNH) as controls. Differentially circulating miRNAs were subse-
quently validated in 88 pancreatic juice samples from 50 PDAC, 19 chronic pancreatitis (CP) pa-
tients and 19 NPNH controls. A marked difference in the profiles of four circulating miRNAs 
(miR-205, miR-210, miR-492, and miR-1427) was observed in pancreatic juice collected from pa-
tients with PDAC and those without pancreatic disease. Elevated levels of the four miRNAs to-
gether predicted PDAC with a specificity of 88% and sensitivity of 87%. Inclusion of serum CA19-9 
level increased the sensitivity to 91% and the specificity to 100%. Enrichment of the four miRNAs 
in pancreatic juice was associated with decreased OS, as was the combination of miR-205 and 
miR-210. Higher contents of miR-205 and miR-210 were also associated with lymph node me-
tastasis. Elevated levels of circulating miR-205, miR-210, miR-492, and miR-1247 in pancreatic juice 
are, therefore, promising candidate biomarkers of disease and poor prognosis in patients with 
PDAC. 
Key words: miRNA; circulating; biomarker; pancreatic juice; pancreatic cancer. 
Introduction 
Pancreatic cancer is the fourth leading cause of 
cancer-related deaths in the United States, with a 
5-year survival rate of about 6% (1). When the tumor 
is detected at an early stage, surgical resection and 
adjuvant chemotherapy or radiotherapy can increase 
the 5-year survival rate to 15-40% (2). Thus, screening 
strategies for detection of early stage cancer or pre-
cursor lesions in individuals at highest risk, as well as 
pancreatic cancer biomarker assays for biological 
fluids, are urgently needed to reduce the high mor-
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bidity and mortality associated with this malignancy.  
Exocrine pancreatic secretions, or pancreatic 
juice, collected from the second part of the duodenum 
after stimulation with intravenous synthetic human 
secretin using an upper endoscope (3-5) have been 
analyzed for molecular markers associated with pan-
creatic ductal adenocarcinoma (PDAC) (6, 7). Protein 
and gene expression profiles in the pancreatic juice of 
patients with PDAC have revealed novel protein 
markers and indicator genes that might be useful for 
PDAC diagnosis (8, 9). More recently, NGAL and 
MIC-1 in pancreatic juice were reported to be useful 
markers for diagnosing benign and malignant disease 
of the pancreas (10). However, since tumor-associated 
proteins may constitute only a minor fraction of the 
vast and dynamic range of proteins in blood plasma 
and other body fluids, proteomic-based strategies for 
identification of circulating cancer biomarkers have 
had limited success so far (11). 
MicroRNAs (miRNAs) are a class of conserved 
small non-coding RNAs, which regulate gene expres-
sion via complementarity with the 3'-untranslated 
region of their target mRNAs, repressing translation 
and causing degradation of multiple target mRNAs 
(12). MicroRNAs have critical regulatory functions in 
cell development, proliferation, differentiation, 
apoptosis, and stress response. A number of studies in 
the past few years have established the regulatory 
roles of miRNAs in complex genetic networks un-
derlying various cellular pathways (13). Aberrant 
expression of several miRNAs has been detected in 
PDAC and its precursor, pancreatic intraepithelial 
neoplasm (14). Varying levels of circulating miRNAs 
in body fluids have been associated with corre-
sponding tumor-specific aberrant expression and 
proposed to represent novel biomarkers for detection 
and diagnosis of various cancers (15, 16). We have 
earlier demonstrated that miRNAs in the plasma of 
patients with pancreatic ductal adenocarcinoma 
(PDAC) may serve as novel blood-based biomarkers 
of disease (17). Serum and pancreatic cyst fluid levels 
of miR-21, miR-210 and miR-155 have been found 
elevated in patients with PDAC (18-21). Elevated se-
rum level of miR-1290 has recently been reported to 
accurately distinguish patients with low stage pan-
creatic cancer from healthy and disease controls (22).  
Altered levels of miRNAs in blood and body 
fluids can distinguish patients with cancer from 
healthy individuals (16, 17, 23). In view of a published 
report that relative expression levels of miR-21 and 
miR-155 in tissue and pancreatic juice from PDAC 
patients were significantly higher than those with 
chronic pancreatitis (24), it appears that unbiased 
profiling of circulating miRNAs in pancreatic juice 
may offer a viable approach for developing reliable 
biomarker assays for detecting PDAC. In this study, 
we performed microarray profiling of miRNAs in the 
pancreatic juice of patients with PDAC compared 
with those from individuals with chronic pancreatitis 
and non-pancreatic disease controls to investigate the 
utility of differentially circulating miRNAs as bi-
omarkers for pancreatic cancer. 
Materials and Methods  
Patients 
This prospective study was approved by the 
Mayo Clinic and M. D. Anderson Cancer Center In-
stitutional Review Boards. Patients presenting at the 
Mayo Clinic with epigastric pain or discomfort war-
ranting evaluation by endoscopic ultrasound-guided 
fine needle aspiration and later diagnosed with 
chronic pancreatitis (CP), pancreatic cancer or no 
pancreatic disease (non-pancreatic, non-healthy 
[NPNH] controls) were enrolled. Pancreatic juice and 
serum samples were collected. Sera were assayed for 
CA19-9 and the definitive final diagnosis was made. A 
multiphase, case–control study was designed to iden-
tify pancreatic juice miRNAs as potential markers for 
PDAC. In the initial biomarker identification stage, 
miRNA microarray profiling was performed on six 
pancreatic juice samples of PDAC patients and two 
pooled pancreatic juice samples from 6 NPNH con-
trols to assay the circulating miRNA profiles. Valida-
tion of four differentially enriched miRNAs was then 
performed using qRT-PCR assay. All the pancreatic 
juice samples were separated randomly into training 
set (6 PDAC and 6 NPNH controls) and validation set 
(44 PDAC, 19 CP and13 NPNH controls) prior to 
analysis from a total of 88 patients enrolled in the 
study as described previously (10).  
Collection of Secretin-Stimulated Exocrine 
Pancreatic Secretions (Pancreatic Juice) 
All patients underwent upper endoscopic intu-
bation after an overnight fast. Patients were moder-
ately sedated with midazolam and meperidine before 
the procedure. Synthetic human secretin (ChiRhoSt-
im; ChiRhoClin Inc, Burtonsville, MD) at a dose of 0.2 
μg/kg (or a total dose of 16 μg) was administered 
intravenously for 1 minute immediately before endo-
scopic intubation. Gastric fluid was aspirated before 
intubation of the pylorus to minimize contamination. 
With the endoscope positioned in the second portion 
of the duodenum, opposite the papilla of Vater 
(without cannulation), a 2.3-mm plastic aspiration 
catheter (Hobbs Medical, Stafford Springs, CT) was 
passed through the biopsy channel of the endoscope 
until it was visible on the endoscopic monitor screen. 
Pancreatic juice exiting the papilla was then suctioned 
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through the catheter for 10 minutes into a dry 20-mL 
tube attached to the proximal end of the catheter. On 
average, 5-8 mL of fluid was collected from each pa-
tient. The collected fluid was immediately aliquoted 
into 2-mL vials, snap-frozen in liquid nitrogen, and 
stored at -80°C until assays for miRNA microarrays 
and real-time polymerase chain reaction were per-
formed. A pan-protease inhibitor cocktail pill (Roche 
Diagnostic Corporation, Indianapolis, IN) was added 
to the collected pancreatic juice to inhibit proteolytic 
degradation. 
Determination of Final Diagnosis 
Three gastroenterologists (Massimo Raimondo, 
Michael B. Wallace, and Timothy A. Woodward), who 
were blinded to the results of the miRNA assays, de-
termined the final diagnosis of the patients on the 
basis of clinical history and laboratory, radiologic 
(computed tomography or magnetic resonance im-
aging), or endoscopic (endoscopic ultrasound or en-
doscopic retrograde cholangiopancreatographic) 
findings (chronic pancreatitis) and cytologic or histo-
logic findings (for those with pancreatic ductal ade-
nocarcinoma). Patients with no prior history of pan-
creatic disease and who had normal pancreatic test 
results (ultrasound, cholangiopancreatography, 
computed tomography, or magnetic resonance imag-
ing) were deemed to have normal pancreata and thus 
considered to be non-pancreatic, non-healthy (NPNH) 
controls. 
CA19-9 Measurement 
Concentrations of CA19-9 in the pancreatic juice 
and serum of patients were measured, as described 
previously (10). Briefly, CA19-9 antigen concentration 
was determined using a solid-phase radioimmuno-
assay (Centocor, Malvern, PA), according to the 
manufacturer’s instructions. Quantities of CA19-9 
were expressed in arbitrary units (U/mL) with 1 unit 
of activity corresponding to approximately 0.8 ng of 
purified antigenic protein for CA19-9. 
miRNA Extraction and Purification 
Pancreatic juice was cleared through centrifuga-
tion at 1,300 × g at 4°C for 10 minutes and stored at 
-80°C. Total RNA was extracted and purified from all 
pancreatic juice samples. For the purpose, cleared 
pancreatic juice was mixed with Trizol LS (1:3 ratio; 
Life Technologies, Grand Island, NY), and after phase 
separation by centrifugation, the aqueous phase was 
extracted once with phenol/chloroform and added to 
ethanol before being applied directly to a mirVana 
miRNA column (Ambion, Austin, TX) according to 
the manufacturer’s instructions. The concentration of 
RNA samples was quantified using NanoDrop 2000 
(NanoDrop, Wilmington, DE). The total amount of 
RNA extracted from 500 µL of pancreatic juice ranged 
from 0.21 to 18.90 µg (mean, 1.34 µg). 
miRNA Microarray Labeling, Hybridization, 
and Data Analysis 
The G4470A Agilent human miRNA microarray 
(Agilent Technologies, Santa Clara, CA) was used to 
profile miRNA. RNA labeling and hybridization were 
performed using the Agilent miRNA labeling reagent 
and hybridization kit according to the manufacturer’s 
protocol. Samples containing 100 ng of RNA were 
labeled with pCp-Cy3 using T4 RNA ligase (Ambion) 
and hybridized to microarrays. Microarrays were 
scanned using an Agilent microarray scanner, data 
were extracted, and array quality control was per-
formed using Agilent Feature Extraction software. 
The AgiMicroRna package was used to process Ag-
ilent miRNA array data. In addition, hierarchical 
clustering was performed using Pearson correlation 
metrics with Ward’s linkage. 
Quantitative Real-Time Polymerase Chain 
Reaction (qRT-PCR) Analysis 
Taqman miRNA assays (Applied Biosystems, 
Foster City, CA) were used to perform expression 
profiling of the miRNAs of interest. RNA was pre-
treated with DNase (Invitrogen). Ten ng of 
DNAse-treated RNA from each sample of pancreatic 
juice was used for each assay. Assays were performed 
in 15-μL reactions containing the reverse transcription 
mixture and Taqman primer mix. miRNA expression 
levels were quantified using the ViiA™ 7 Real-Time 
PCR System (Life Technologies). Relative expression 
of the mature miRNAs in terms of fold change in the 
test samples (PDAC or CP) compared with the 
non-pancreatic, non-healthy (NPNH) controls was 
calculated using the comparative CT (2-ΔΔCT) method, 
using RNU6B as the endogenous control to normalize 
the data, where CT (cycle threshold) is defined as the 
number of cycles required for the FAM signal to cross 
the threshold in real-time PCR. ΔCT was calculated by 
subtracting the CT values of RNU6B from the CT 
values of the miRNA of interest. ΔΔCT was then cal-
culated by subtracting the mean ΔCT of NPNH con-
trols from the ΔCT of test samples (PDAC or CP). 
Locked Nucleic Acid In Situ Hybridization 
(LNA-ISH) 
For analyzing miRNA expression formalin-fixed, 
paraffin-embedded tumor tissue slides were toasted, 
de-waxed in xylenes, and rehydrated through an 
ethanol dilution series. Tissue sections were digested 
with 15 μg/mL proteinase K and then treated with 3% 
hydrogen peroxide. Tissue sections were then sub-
jected to prehybridization solution at 50°C for 30 
 Journal of Cancer 2014, Vol. 5 
 
http://www.jcancer.org 
699 
minutes. The prehybridization solution was replaced 
with 50 μL of hybridization solution containing 10 
pmol of the fluorescein isothiocyanate–labeled LNA 
probes for the miRNAs. Slides were blocked with 5% 
bovine serum albumin, incubated with an-
ti-Fluorescein-HRP conjugated antibodies, and sub-
jected to the CSA II Biotin-free Tyramide Signal Am-
plification System Kit (DAKO, Carpenteria, CA) as 
described previously (25). 
Statistical Analysis 
All clinicopathologic variables and miRNA ex-
pression levels in pancreatic juice were analyzed us-
ing SPSS v19 (SPSS Inc, Chicago, IL). Unpaired t tests 
were used to compare pancreatic juice miRNA ex-
pression between groups and p values <0.05 were 
considered statistically significant. The relationship 
between miRNA expression and overall survival (OS) 
was evaluated using Cox proportional hazards re-
gression models. Hazard ratios and 95% confidence 
intervals (CIs) were calculated, with adjustments 
made for sex, ethnicity, and other clinical factors that 
were significant predictors of OS in multivariate Cox 
regression models. Receiver operating characteristic 
(ROC) curves were constructed and the area under 
the curve (AUC) was calculated to evaluate the ability 
of each individual miRNA and CA19-9 either indi-
vidually or in combination to detect pancreatic cancer. 
OS curves were estimated using the Kaplan-Meier 
method. The median expression level of each miRNA 
was used as the cutoff point in Kaplan-Meier survival 
analysis. 
Results 
Patient Characteristics  
Among the 88 patients enrolled in the study 
(training and validation sets), 19 were NPNH con-
trols, 19 were diagnosed with CP, and 50 were 
diagnosed with PDAC. Patient demographic 
and clinicopathologic information is presented 
in Table 1. Among the 50 patients with PDAC, 
univariate analysis by SPSS showed that OS 
did not differ by age, sex, smoking and alcohol 
history, diabetes mellitus, CA19-9 findings, or 
lymph node involvement. The median OS du-
ration of the 50 patients with PDAC was 7.90 
months (95% CI, 0.417-41.09 months). Howev-
er, the median follow-up time was 12.43 
months for the patients who were still alive at 
the time of analysis. Well to moderate tumor 
differentiation was associated with increased 
OS duration (P=0.005). 
Pancreatic Juice miRNA Profiles of 
Patients with PDAC 
The pancreatic juice miRNA microarray 
profiles of 6 patients with PDAC were com-
pared with those of pooled samples from 6 
NPNH controls. Hierarchical clustering of 
miRNA expression using the Pearson correla-
tion distance metric and Ward’s linkage re-
vealed clusters of patients with PDAC and 
NPNH controls after Robust Multi-Array Av-
erage (RMA) normalization (Fig. 1A). Levels of 
49 miRNAs differed by at least 1.5-fold in the 
pancreatic juice of patients with PDAC com-
pared with that of NPNH controls (P < 0.05; 
Additional File 1: Supplementary Table S1). To 
statistically analyze the similarity of pancreatic 
juice miRNA profiles among patients with 
PDAC, we generated a dendrogram of can-
cer-dependent miRNAs, in which PDAC pan-
creatic juice samples with similar miRNA pro-
Table 1. Characteristics of the Study Population. 
Characteristic 
 
NPNH        
(n = 19) 
 
CP   (n = 
19) 
 
PDAC (n = 50) 
No. of 
patients 
No. of 
death 
MST 
(months) 
P 
value 
Age, years      0.188 
<60 9 8 12 7 10.73  
61-70 6 5 18 15 8.70  
>70 4 6 20 13 4.37  
Sex       0.109 
Male  5 11 30 22 5.70  
Female  14 8 20 13 10.73  
Ethnicity       0.047 
White  16 17 48 34 8.00  
Black  2 1 2 1 2.07  
Hispanic  1 0 0 0   
Asian  0 1 0 0   
Smoking historya       0.347 
Current  2 7 9 6 5.63  
Former  6 6 15 8 8.70  
Never  11 6 25 21 5.20  
History of alco-
hol usea   
     0.696 
Current  9 9 24 14 6.77  
Former  5 5 8 7 8.70  
Never  5 5 17 14 10.27  
Diabetes melli-
tusa 
     0.451 
Yes  3 5 10 7 3.93  
No  16 14 39 28 8.70  
CA19-9, U/mL      0.404 
<50 9 6 6 3 9.77  
51-500 1 1 4 2 2.07  
501-1500 3 4 5 4 2.33  
>1500 6 8 35 26 7.90  
Lymph node b      0.290 
0 19 19 35 26 8.00  
1 0 0 13 9 6.77  
Tumor differen-
tiationa 
     0.005 
Well to moderate - - 9 5 18.33  
Poor or not 
available 
- - 40 30 5.63  
aSmoking history, history of alcohol use, diabetes status and tumor differentiation were not 
available for 1 patient with PDAC. b lymph node was not available for 2 patient with PDAC. 
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files were grouped together (Fig. 1B). Multiple miR-
NAs with elevated profiles in the pancreatic juice, 
including miR-205 and miR-210, which are known to 
be overexpressed in PDAC tissue (26, 27), were found 
to segregate into distinct clusters in the dendrogram 
generated. We selected miR-492 and miR-1247, the top 
two miRNAs in the same cluster as miR-205 and 
miR-210, which have not been previously reported in 
PDAC, for validation as novel candidate biomarkers 
circulating at elevated levels in the pancreatic juice of 
patients with PDAC.  
Quantitative Real-Time Polymerase Chain 
Reaction (qRT-PCR) Analysis of Candidate 
miRNAs 
To validate the differential enrichment of four 
candidate miRNA biomarkers in pancreatic juice, 
identified on expression microarrays, we used 
qRT-PCR assay for 4 miRNAs (miR-205, miR-210, 
miR-492, and miR-1247) in individual pancreatic juice 
samples (training set). The relative abundance of four 
miRNAs, normalized to the level of RNU6B, signifi-
cantly varied in pancreatic juice samples from patients 
with PDAC and NPNH. The levels of four miRNAs 
were further assayed in a larger cohort consisting of 
an independent set of pancreatic juice samples (vali-
dation set). The p values revealed that the levels of 
these miRNAs showed statistically significant differ-
ences among patients in these three groups (PDAC, 
CP and NPNH; miR-205, P = 0.04; miR-210, P = 
1.90E-05; miR-492, P = 0.005; miR-1247, P = 0.04; Fig. 
2A and Table 2). The mean fold changes of miRNAs 
and the p values reflected segregation of PDAC, CP, 
and NPNH samples in terms of varying miRNA lev-
els, with the levels relatively high in PDAC, low in 
controls and intermediate in CP although the differ-
ence between PDAC and CP were not significant.  
 
 
Figure 1. Hierarchical clustering analysis of microRNA microarray expression profile. (A) Clusters of patients with pancreatic ductal adenocarcinoma (PDAC) and 
non-pancreatic, non-healthy controls (NPNH). (B) Hierarchical clustering of microRNA expression in PDAC pancreatic juice samples with similar miRNA profiles were grouped 
together, which showed that miR-492, miR-1247, miR-205 and miR-210 were in the same cluster.  
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Figure 2. Quantitative real-time polymerase chain reaction (qRT-PCR) and Locked nucleic acid in situ hybridization (LNA-ISH) analysis of expression 
levels of microRNAs. (A) qRT-PCR analysis of relative expression levels of 4 microRNAs (miR-205, miR-210, miR-492, and miR-1247) in pancreatic juice samples from patients 
with pancreatic ductal adenocarcinoma (PDAC), patients with chronic pancreatitis (CP), and non-pancreatic, non-healthy (NPNH) controls. The relative abundance of four 
miRNAs, normalized to the level of RNU6B, significantly varied in pancreatic juice samples from patients with PDAC, CP and NPNH. (B) LNA-ISH-IHC images showing miR-492 
expression in 3 (J101, J16, J39) pancreatic ductal adenocarcinoma tissue samples (magnification ×100). (C) The graph shows qRT-PCR results for miR-492 in pancreatic juice 
samples from the same patients.  
 
Table 2. MicroRNA (miRNA) expression in samples of pancreatic 
juice from patients with pancreatic ductal adenocarcinoma 
(PDAC); Chronic pancreatitis (CP); Non-pancreatic, non-healthy 
controls (NPNH). 
miRNA 
expression 
NPNH samples 
(n = 19), no. (%) 
CP samples (n 
= 19), no. (%) 
PDAC samples 
(n = 50), no. (%) 
P value 
miR-205    0.04 
Low 14 (74) 10 (53) 20 (40)  
High 5 (26) 9 (47) 30 (60)  
miR-210    1.90E-05 
Low 18 (95) 10 (53) 16 (32)  
High 1 (5) 9 (47) 34 (68)  
miR-492    0.005 
Low 16 (84) 10 (53) 20 (40)  
High 3 (16) 9 (47) 30 (60)  
miR-1247     0.04 
Low 13 (76) 9 (47) 20 (41)  
High 4 (24) 10 (53) 29 (59)  
miR-205/ 
miR-210 
   8.31E-04 
0-1 19 (100) 13 (68) 26 (52)  
2 0 6 (32) 24 (48)  
 
 
The relative increase in the levels of the candi-
date miRNAs in pancreatic juice samples from pa-
tients with PDAC was significantly higher than in 
samples from NPNH controls (miR-205, P = 0.009; 
miR-210, P = 0.010; miR-492, P= 0.003; miR-1247, P= 
0.041; Additional File 1: Supplementary Table S2). 
These results were in good agreement with microar-
ray and training set results. Levels of the candidate 
miRNAs were higher in the CP samples than in the 
NPNH samples, although the difference was statisti-
cally significant for only miR-492. Levels of miR-205, 
miR-210, and miR-1247 did not differ between the CP 
samples and the NPNH samples. These miRNAs were 
significantly elevated in PDAC samples compared 
with NPNH samples but not compared with the CP 
samples.  
Expression of miRNAs in PDAC Tumor 
Samples 
To investigate whether varying levels of miR-
NAs detected in the pancreatic juice of patients with 
PDAC reflected differential expression of the miRNAs 
in pancreatic tumor tissues, we performed LNA-ISH 
with the miRNA probes on a limited set of 12 availa-
ble tumor tissue samples. miRNAs detected by 
LNA-ISH in the tumor tissues (Fig. 2B) were con-
sistent with those detected in the corresponding pan-
creatic juice samples (Fig. 2C).  
To estimate miRNA-492 and miRNA-1247 dif-
ferential expression in PDAC, qRT-PCR analysis of 
miRNA expression was also undertaken in 34 paired 
samples of PDAC tissue and adjacent normal tissue. 
Twenty PDAC tumor samples (59%) showed in-
creased expression of miR-492, and only 13 samples 
(38%) showed increased expression of miR-1247 (data 
not shown).  
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Pancreatic Juice miRNA Profiles as 
Biomarkers of PDAC 
The ability of the 4 miRNAs to differentiate 
PDAC pancreatic juice samples from NPNH pancre-
atic juice samples was assessed using ROC curves, 
which indicated that the 4 miRNAs are candidate 
biomarker of PDAC (miR-205 AUC = 0.68; miR-210 
AUC = 0.84; miR-492 AUC = 0.80; miR-1247 AUC = 
0.63). For all 4 miRNAs combined, the AUC was 0.92, 
documenting that the altered levels of the 4 miRNAs 
in pancreatic juice can differentiate patients with 
PDAC from NPNH controls. When serum expression 
of CA19-9 was considered along with the 4 miRNAs, 
the AUC was 0.99, which was significantly improved 
compared with both CA19-9 alone (AUC = 0.89) and 
the combination of the 4 miRNAs without CA19-9 
(Fig. 3A and Additional File 1: Supplementary Table 
S3).  
ROC curves helped determine the sensitivities 
and specificities of the miRNAs at various cutoff val-
ues (Supplementary Table S3). Using the optimal 
cutoff points, sensitivity and specificity were 64% and 
74%, respectively, for miR-205; 76% and 95% for 
miR-210; 73% and 82% for miR-492; and 53% and 88% 
for miR-1247. The sensitivity and specificity for the 4 
miRNAs combined were 87% and 88%, respectively. 
Finally, the combination of the 4 miRNAs plus 
CA19-9 had a sensitivity of 91% and a specificity of 
100%, which was significantly improved than CA 19-9 
alone (77% sensitivity, 93% specificity).  
Pancreatic Juice miRNAs as Biomarkers for 
PDAC Prognosis, Tumor Differentiation, and 
Lymph Node Metastasis 
We performed Kaplan-Meier analyses to assess 
the relationship between pancreatic juice miRNA lev-
els and clinical outcome, using the median expression 
level as a cutoff (at or above the median = high ex-
pression; below the median = low expression), in 36 
PDAC patients for whom all the clinical data were 
available. Multivariate Cox regression models for in-
dividual miRNAs and combinations of miRNAs are 
shown in Table 3. Patients with low levels of miR-205 
or miR-210 (individually) had longer OS durations 
than patients with high levels of these miRNAs, but 
the difference was not statistically significant 
(miR-205 log-rank P = 0.166; miR-210 log-rank P = 
0.211). However, we found that elevated levels of all 4 
miRNAs was associated with shorter OS (log-rank P = 
0.050), as was high expression of both miR-205 and 
miR-210 together (log-rank P = 0.029). Patients with 
low levels of both miR-205 and miR-210 tended to 
have longer OS durations than did patients with high 
levels of both miR-205 and miR-210 (Fig. 3B).  
Patients with low levels of both miR-205 and 
miR-210 appeared less likely to have lymph node 
metastasis than patients with high levels of both 
miR-205 and miR-210 (Additional File 1: Supplemen-
tary Table S4). Patients with low levels of miR-205 
also tended to have well to moderately differentiated 
tumors (P = 0.001) (Additional File 1: Supplementary 
Table S4).  
 
 
Figure 3. Receiver operating characteristic curves (ROC) and Kaplan-Meier plots showing association of pancreatic juice miRNA profiles in PDAC 
patients and their clinical outcome. (A) Receiver operating characteristic curves showing expression levels of individual microRNAs (miR-205, miR-210, miR-492, and 
miR-1247), CA19-9, and a combination. (B) Kaplan-Meier overall survival curves for patients with pancreatic ductal adenocarcinoma with high levels of both miR-205 and miR-210 
at or above the median (shown in green); either miR-205 or miR-210, or neither upregulated in pancreatic juice samples (shown in blue). The curves were compared using 
univariate (log-rank) analysis. 
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Table 3. Median overall survival time (MST) of pancreatic ductal 
adenocarcinoma (PDAC) patients with high and low levels of 
circulating miRNAs in pancreatic juice.  
miRNA 
expression 
No. of 
patients 
No. of 
deaths 
MST, 
months 
Log-rank P 
value 
HR (95% CI)a P 
value 
miR-205       
Low b 15 13 12.40 0.166 1.46(0.66-3.12) 0.347 
High c 21 20 5.63    
miR-210       
Low 11 9 11.33 0.211 1.78(0.66-4.80) 0.254 
High 25 24 6.77    
miR-492       
Low 17 15 7.90 0.678 0.82(0.36-1.83) 0.620 
High 19 18 8.70    
niR-1247        
Low 14 14 6.77 0.586 1.47(0.67-3.23) 0.334 
High 21 18 7.90    
miR-205/miR
-210/  
miR-492/miR
-1247  
      
0-3d 32 29 8.70    
4e 4 4 3.77 0.050 2.87 (0.93-8.87) 0.067 
miR-205/miR
-210 
      
0-1f 18 15 11.33    
2g 18 18 3.93 0.029 2.14 (1.06-4.29) 0.030 
aHazard ratios (HR) derived from multivariate Cox regression models adjusted for 
sex, ethnicity, CA19-9 levels, and stage;  
bLow < the median expression level; cHigh ≥ the median expression level; d0-3: 
Patients with ≤ three miRNAs (miR-205, miR-210, miR-492 and miR-1247) upregu-
lated in pancreatic juice; e4: Patients with four miRNAs upregulated in pancreatic 
juice; f0-1: Patients with either miR-205 or miR-210 upregulated in pancreatic juice; 
g2: Both miR-205 and miR-210 upregulated in pancreatic juice of the same patient. 
 
Discussion 
Elevated levels of microRNAs have been de-
tected in precursor lesions of pancreatic cancer and 
were also associated with poorer survival of pancre-
atic cancer patients (26, 27). Our results indicate that 
miR-205, miR-210, miR-492, and miR-1247 in pancre-
atic juice are candidate biomarkers of PDAC, which 
perform even better when combined with serum 
CA19-9 levels. We also found that expression of these 
4 miRNAs is associated with decreased OS in patients 
with PDAC. In addition, elevated amount of miR-205 
and miR-210 was associated with lymph node metas-
tasis, and expression of miR-205 was associated with 
poorly differentiated tumors, both indicators of worse 
prognosis. These findings suggest that pancreatic 
juice levels of miR-205, miR-210, miR-492, and 
miR-1247, as a combined signature can predict the 
clinical outcome of patients with PDAC.  
Microarray analyses identified 49 miRNAs as 
differentially enriched in the pancreatic juice of pa-
tients with PDAC compared with controls; of these, 
miR-200a, miR-200b, and miR-30b have also been 
found to be upregulated in PDAC cells and tumor 
tissue (28). In addition, high expression of miR-205 
was found in head and neck cancer cell lines (29), 
squamous cell carcinoma cell lines (30), and cervical 
cancer cell lines (31), as well as in clinical samples of 
metastatic head and neck squamous cell carcinoma 
(32), cervical cancer (31), non-small cell lung cancer 
(33), and endometrial cancer (34). Expression of 
miR-205 in clinical prostate cancer samples was asso-
ciated with prostate cancer progression (35) and in-
vasive bladder cancers (36). Up-regulation of miR-205 
was also found to precede phenotypic changes in 
ductal cells in a conditional KRAS (G12D) mouse 
model of pancreatic cancer (27). 
Aberrant high expression of miR-210 has been 
detected in many tumors (26, 37-42)., Elevated 
miR-210 has been implicated in tumor progression 
(43) and is associated with negative clinical outcomes 
(26, 41, 42). Interestingly, increased plasma miR-210 
levels were associated with lymph node metastases 
and trastuzumab resistance in breast cancer patients 
(44). These findings are to some extent consistent with 
our current observation that high miR-205 and 
miR-210 levels in pancreatic juice correlate with de-
creased OS, poorly differentiated tumors, and lymph 
node metastasis. These observations make a compel-
ling case for miR-205 and miR-210 in pancreatic juice 
as informative biomarkers for PDAC. 
A recent study has reported miR-1247 to be 
down-regulated in pancreatic cancer correlating with 
tumor grade and shorter overall survival of the pa-
tients (45). miR-492 has also been shown to potentially 
play an important role in the progression of malignant 
embryonal liver tumors (46). Although our study did 
not reveal significant differences in the levels of these 
miRNAs between CP and PDAC, it is plausible that 
this was due to relatively small sample size and thus 
lack of enough statistical power in the current study. 
However, in view of these miRNAs discriminating 
PDAC from NPNH controls with reasonably high 
sensitivity and specificity as well as showing signifi-
cant correlation with decreased OS and lymph node 
metastasis, it is important that the miRNA signature 
be investigated in a larger patient population in the 
future. The current finding of the four miRNAs sig-
nature in pancreatic juice as a biomarker panel of 
pancreatic cancer suggest that these miRNAs are in-
volved in critical cancer relevant genetic networks 
deregulated in PDAC.  
Collection of pancreatic juice is a minimally in-
vasive procedure which can easily detect circulating 
or secreted miRNAs as concentrations of miRNAs are 
higher than in blood (serum or plasma). This is im-
portant as circulating miRNAs in blood can poten-
tially decrease over time whereas they can be still de-
tectable in pancreatic juice. For detection of early 
PDAC, this procedure will be preferable as concen-
trations of miRNAs will be higher in pancreatic juice 
than in blood. Moreover, our technique can be used as 
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part of routine diagnostic procedure to establish di-
agnosis/staging of PDAC and does not involve can-
nulation of pancreatic duct to collect pancreatic juice.  
Finally, we recognize that the procedure is ex-
pensive if secretin is used and more invasive unlike 
detecting miRNAs in blood., The collection and stor-
age procedures need to be standardized for a broader 
applicability of this technique. It is important to have 
stringent quality control standards for collection of 
pancreatic juice and pancreatic juice miRNAs expres-
sion analysis besides ensuring that sample size is ad-
equate for selecting the most informative candidate 
biomarker miRNAs capable of discriminating patients 
with pancreatic cancer, pancreatitis versus no pan-
creatic disease.  
In summary, our study demonstrates that 
miRNAs in exocrine pancreatic secretions are prom-
ising biomarkers of PDAC. Further comprehensive 
molecular and functional characterizations of miR-
NAs circulating at altered levels in pancreatic juice are 
warranted to elucidate the role of these miRNAs in 
pancreatic carcinogenesis and validate them in larger 
sample cohorts as biomarker panels for detection, 
prognosis as well as response to therapy for this 
highly lethal malignancy.  
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